n
 
About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Monday, February 5th, 2018

The QualityStocks
Daily Stock List

graphic
graphic

Medizone International, Inc. (MZEI)

Zacks, AwesomePennyStocks, MarketWatch, StockNewsUnion, OTC Markets, Stockhouse, and Amigo Bulls reported on Medizone International, Inc. (MZEI), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Medizone International, Inc. is centered on commercializing the AsepticSure® System, a premier disinfectant technology. It developed the AsepticSure® System to combine oxidative compounds (O3 and H202) to produce an innovative mixture of free radicals (H2O3 known as trioxidane) with significantly higher oxidative potential than ozone or hydrogen peroxide alone. Medizone International has its corporate office in Kalamazoo, Michigan.

The AsepticSure® hospital disinfection system is a portable, affordable, easily operated system. It can be used by trained maintenance staff.  The AsepticSure® hospital disinfection system is placed in the center of the room to be cleaned.  Vents and doors are subsequently sealed with a removable 3M-tape.

This system is turned on from outside of the room via a remote wireless computer interface. The room is filled with an innovative and patented gas formula. This is ozone-based to specific humidity and charge strength.

After the charge period, the disinfection process is remotely turned off. Moreover a separate technology is utilized, which restores the atmosphere inside the room to EPA (Environmental Protection Agency) standards. The result leaves the treated room devoid of pathogens. In its place is a sweet, fresh oxygen-charged atmosphere.

Recently, Medizone International and Aglon a/s announced that they entered into an agreement for the introduction and distribution of AsepticSure® in the Nordic Region. Medizone granted Aglon a/s exclusive distribution rights for the AsepticSure® system in Norway, Sweden, Denmark, Finland and Iceland.

In addition, Medizone International recently announced the conclusion of an exclusive Product Supply and License Agreement with Innovasource, LLC.

With this Supply Agreement, Innovasource will supply its custom-formulated, EPA-registered hydrogen peroxide based disinfectant product to Medizone International for use in the AsepticSure® Disinfection System.

Furthermore, Innovasource granted to Medizone an exclusive, non-transferable limited license to use Innovasource's intellectual property (IP) in the marketing and sale of the AsepticSure® Disinfection System in the U.S.  The Supply Agreement has a five-year term. It will automatically renew for successive two-year terms. Innovasource is a foremost manufacturer of cleaning, deodorizing, and disinfecting products.

In late November, Medizone International announced that it will meet with representatives of the U.S. Food and Drug Administration (FDA) on January 18, 2018. This meeting is to discuss the planned submission of a marketing application for AsepticSure®.  The FDA has confirmed that the Company’s pre-submission filing contains all required information to permit the FDA to proceed with further review of the submission.

Medizone International, Inc. (MZEI), closed Monday's trading session at $0.039125, up 2.65%, on 269,000 volume with 9 trades. The average volume for the last 60 days is 365,524 and the stock's 52-week low/high is $0.026/$0.15.

Brightlane Corp. (BTLN)

MarketWatch, InvestorsHub, OTC Markets, Simply Wall St, Stockhouse, Barchart, 4-Traders, Morningstar, GuruFocus, Capital Cube, YCharts, InFrontAnalytics, Penny Stock Tweets, Market Exclusive, Marketwired, and TradingView reported on Brightlane Corp. (BTLN), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Brightlane Corp. is a real estate operating company listed on the OTC Markets Group’s OTCQB. The Company provides an alternative pathway to home ownership by way of a right-to-purchase program after meeting certain criteria. Brightlane concentrates on acquiring, renovating, managing, and leasing low priced single-family homes mainly in the United States. The Company has its corporate office in Houston, Texas.

Brightlane provides opportunities in the affordable housing market including reasonable rents and leases. At present, the Company acquires single-family homes and portfolios of single-family homes. It pursues the acquisition of these kinds of homes via one-off purchases, the purchase of portfolios, as well as other methods of acquisition.

Brightlane’s criteria for acquisitions of single-family home portfolios are a portfolio size of 5 to 500 homes. The Company’s acquisition efforts are chiefly focused in the Southeast, Midwest, and Southwest regions of the U.S.

Brightlane is looking for growth in ancillary markets. It is enhancing its business plan to access higher value and higher profit market segments with synergistic effects to its business model.

The Company is working to expand its business model into different areas. These areas include multifamily, active adult living, and student housing. These areas also include build-to-rent in the affordable housing space, non-performing notes, as well as credit reporting. In addition, Brightlane will be executing a ground up construction platform of rental single and multifamily products.

Mr. Steve Helm, Brightlane’s President and Chief Executive Officer, stated, "Our market segment has evolved and Brightlane is responding accordingly. With the current market evolution and market dynamics, we have now better aligned our acquisition strategies to most effectively utilize our $5 million credit facility and gain access to additional finance."

Furthermore, Mr. Helm stated, "One of our goals for 2018, which we believe can be accomplished this calendar year by adhering to our acquisition and corporate development initiatives, is to apply for admission to the NASDAQ Exchange."

Brightlane Corp. (BTLN), closed Monday's trading session at $1.00, down 40.83%, on 500 volume with 2 trades. The average volume for the last 60 days is 1,685 and the stock's 52-week low/high is $0.51/$4.25.

RepliCel Life Sciences, Inc. (REPCF)

OTCPicks, Greenbackers, Investor Spec Sheet, StockGuru, TheStockAdvisor, 24-7 Stock Alert, Beacon Equity Research, Crazy Carl, Global Equity Report, The Green Baron, Club Penny Stocks Network, Streetwise Reports, InvestorSoup, Penny Stock Explosion, SmallCapReview, Stock Preacher, Penny Stocks Finder, ShazamStocks, and StockHideout reported earlier on RepliCel Life Sciences, Inc. (REPCF), and today we report on the Company, here at the QualityStocks Daily Newsletter.

RepliCel Life Sciences, Inc. is a regenerative medicine company listed on the OTC Markets’ OTCQB. The Company concentrates on the development of cell therapies for aesthetic and orthopedic conditions. These include aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. All of its product candidates are based upon RepliCel’s unique technology using cell populations isolated from a patient's healthy hair follicles. RepliCel Life Sciences has its headquarters in Vancouver, British Columbia.

The Company’s product pipeline consists of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, as well as RCH-01 for hair restoration. Currently, RCH-01 is being co-developed with, and under exclusive license by, Shiseido for certain Asian countries. In addition, RepliCel has developed a proprietary injection device RCI-02, optimized for the administration of its products and licensable for use with other dermatology applications.

RepliCel Life Sciences is investing in research that the Company states has the potential to lead to a number of future products. These include other chronic tendinopathies (patellar tendinosis, tennis elbow, golfer’s elbow, rotator cuff); other dermatologic indications (acne scaring, etc.); gingivitis, and allogeneic versions of the Company’s proven autologous cell therapies.

In September 2017, RepliCel Life Sciences announced the timely arrival of its functioning RCI-02 prototypes. These became ready to be showcased to potential end users and licensing partners.

With these prototypes in-hand, the Company is engaging with important opinion leaders and clinical dermatologists to ask for feedback vitally important to aligning successful early adoption of the device, design clinical studies demonstrating its advantages in select applications, and position RepliCel for an anticipated successful launch of an approved next-generation dermal injector in the European market this year.

Last month, RepliCel Life Sciences announced that it signed a Binding Term Sheet with YOFOTO (China) Health Industry Co. Ltd. (YOFOTO) to establish a strategic partnership in Greater China (Mainland China, Hong Kong, Macau, and Taiwan). The deal involves an up-front investment of USD $6,500,000 and potential pre-commercial, non-dilutive milestones payments of another USD $2,800,000.

Moreover, the Term Sheet commits YOFOTO to another USD $1,000,000 in potential post-commercial non-dilutive milestone payments, several million in dedicated program funding in Greater China over the next five years, and future royalty payments calculated on gross product sales in the Territory.

RepliCel Life Sciences, Inc. (REPCF), closed Monday's trading session at $0.3408, down 3.46%, on 42,940 volume with 11 trades. The average volume for the last 60 days is 17,260 and the stock's 52-week low/high is $0.266/$1.31.

A.I.S. Resources Limited (AISSF)

Wall Street Analyzer, Stockhouse, Barchart, Business Insider, The Street, YCharts, Morningstar, MarketWatch, InvestorsHub, GuruFocus, Stockwatch, and Penny Stock Hub reported on A.I.S. Resources Limited (AISSF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

OTCQB-listed, A.I.S. Resources Limited established in 1967. The Company is managed by experienced, highly qualified professionals who have a long record of accomplishment of success in lithium exploration, production and capital markets. They identify and develop early stage projects globally that have strong potential for growth. A.I.S. Resources has its head office in Nassau, Bahamas. The Company also has a Canadian office in Vancouver, British Columbia.

A.I.S. Resources concentrates on developing significant lithium resource projects in Argentina’s world-renowned Lithium Triangle. The Company has two large projects, Chiron and Guayatayoc. The Chiron Project is 2,732 Ha. The Guayatayoc Project is 5,225 Ha. A.I.S. Resources also has its Vilama Project in the Lithium Triangle. Vilama is 2,500 Ha.

Guayatayoc is an approved borate mine. It encompasses all industrial minerals including lithium. Guayatayoc and Guayatayoc III are in Jujuy Province, 5 kilometers from the town of Abralaite in the Puna plateau. This property encompasses about 5,000 hectares of the Guayatayoc Salar that hosts favorable geology for lithium and boron, positioned adjacent to the El Aguillar mountain range, the source of lithium and boron.

The Chiron Project comprises four concessions in the Salar de Quirón in the Province of Salta, roughly 10 kilometers from the township of Pocitos. Very encouraging results from other, close by, explorers classifies the Chiron Project as having considerable prospectivity.

Recently, A.I.S. Resources Limited announced it was granted an exploration license for seismic and drilling at its Chiron project. This allows A.I.S to quickly progress to a TEM seismic program and then drilling immediately thereafter.

The Company entered into a contract with Quantec Geoscience Argentina S.A. to conduct a 19 point TEM (VES) seismic survey in early January 2018. This work will be completed by February 2018. Preliminary tenders have been received from several drilling companies for an eight hole program of 3,200 meters.

Last week, A.I.S. Resources announced that seismic testing detected three distinct aquifers over a wide-ranging region at its Chiron Project in the Pocitos Salar, Salta Province, Argentina.

Mr. Phil Thomas, A.I.S. Resources’ Chief Operating Officer and Exploration Director stated: "This initial seismic data from Chiron based on the TEM geophysics strongly supports our case for acquiring these strategic concessions. Together with our Guayatayoc Project to the northwest in Jujuy province, where we've made excellent progress with our pilot plant production chemistry, A.I.S. is on track for a breakthrough year as an emerging new producer in the lithium brine space in Argentina."

A.I.S. Resources Limited (AISSF), closed Monday's trading session at $0.5222, up 10.40%, on 63,714 volume with 35 trades. The average volume for the last 60 days is 63,050 and the stock's 52-week low/high is $0.1548/$1.22.

CipherLoc Corp. (CLOK)

InvestorsHub reported earlier on CipherLoc Corp. (CLOK), and we also highlight the Company, here at the QualityStocks Daily Newsletter.

CipherLoc Corp. is a top provider of highly secure data protection technology. The Company has highly innovative solutions based on its patented Polymorphic Cipher Engine. The design of this Engine is to take existing encryption algorithms and makes them better, quicker, stronger, and also extremely scalable. A data security solutions business, CipherLoc lists on the OTC Markets Group’s OTCQB. The Company has its head office in Austin, Texas.

CipherLoc delivers easy-to-deploy software solutions. These solutions can be added to any existing product, service, or application.

Fundamentally, CipherLoc keeps information safe. Its unique technology can be employed to overcome the flaws and inadequacies associated with contemporary encryption algorithms to totally and securely protect the world’s data. Nonetheless, the Company’s technology does not replace existing encryption technologies, it augments them.

The design of CipherLoc’s software solutions are to be easily added to any existing product, service, or application that currently utilizes encryption. Through adding an ironclad layer of protection to a customer’s existing product or service, CipherLoc ensures private information is secure. This is while also preserving the investment a customer has already made in data security.

The Company has a variety of products. These include CipherLoc GATEWAY, CipherLoc SHIELD, CipherLoc EDGE, and CipherLoc ENTERPRISE.

CipherLoc GATEWAY is a data protection software solution. It is targeted for use on server platforms. CipherLoc SHIELD is a data protection solution. It is targeted for use on any platform where information is stored.

CipherLoc EDGE is a data protection software solution. It is targeted for use on mobile devices. CipherLoc ENTERPRISE is a data protection software solution. It is targeted for use on desktop, laptop, and/or tablet devices.

CipherLoc has available a client-side extension to its secure email solution. This extension will permit recipients of emails that have been protected with CipherLoc's inventive data protection technology to decrypt messages so they can be read.

The design is for use with Microsoft Outlook clients. The Company’s client version software will allow messages to be decrypted but not encrypted. For clients wanting to obtain full encrypt and decrypt capabilities, CipherLoc will offer an easy migration path to the full-featured email protection product.

CipherLoc Corp. (CLOK), closed Monday's trading session at $1.68, down 2.33%, on 14,731 volume with 17 trades. The average volume for the last 60 days is 2,332 and the stock's 52-week low/high is $0.81/$3.30.

Hispanica International Delights of America, Inc. (HISP)

InvestorsHub and MarketWatch reported on Hispanica International Delights of America, Inc. (HISP), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

Hispanica International Delights of America, Inc.’s devotion is to building one of the premier companies distributing ethnic food and beverages throughout the U.S. The Company is pursuing a determined acquisition strategy to grow its portfolio of brands and to expand its own wholesale distribution network across the nation. Hispanica International Delights of America (HISP) engages in the distribution of proprietary, licensed, and third-party Hispanic and Ethnic food and beverages across the U.S.

HISP is headquartered in New York, New York. Established in 2013, the Company has distribution operations underway in the New York City Tri-State Region; the Washington, D.C. Metro Area; the Houston Metropolitan Area, and in Los Angeles and the Northern California Region.

The Company also distributes fruit juices, nectars, as well as milk-based products. It will then start to distribute teas, carbonated drinks, dry goods, preserves, frozen foods, and bakery products.

Brands undergoing distribution are under a proprietary basis – via distribution agreements and/or exclusive licensing arrangements. These brands are modeled on the flavors, tastes, and traditions, which have been known for generations among the Hispanic and other ethnic groups.

Hispanica earlier acquired Energy Source Distributors, Inc. This expands its wholesale distribution channels. In addition, HISP has expanded distribution into greater than 2000 retailers. These include Walmart, 7Eleven, Safeway, Nob Hill, Kroger’s owned Food 4 Less, Valero Gas, and Shell Gas chain stores.

HISP also acquired a 20 percent equity interest in Gypsy Crunch, LLC. As part of the transaction, Hispanica gains exclusive nationwide distribution of all Gypsy Crunch products and the option to significantly increase its stake to a controlling interest as the brand continues to grow. Gypsy Crunch is a Portland, Oregon-based all natural granola snack brand enterprise

HISP signed a binding term sheet in 2017 to acquire all the outstanding shares of Giant Beverage Company, Inc. of New York, New York for cash and stock consideration. Giant Beverage is a Direct Store Delivery (DSD) company with eight routes servicing the five boroughs of New York City.

Giant Beverage’s warehousing and logistical capabilities are a vital asset for Hispanica’s continued growth as it works to expand distribution of its own proprietary products into retailers inside New York City and neighboring New Jersey and other parts of the Tri-State Region.

This past November, HISP announced that it completed its acquisition of Victoria’s Kitchen™. Los Angeles, California based, Victoria’s Kitchen™ is an almond water specialty beverage company. This acquisition is expected to speed up Victoria’s Kitchen™ growth and expand national reach through HISP’s proprietary distribution system.

Last month, HISP announced that its Board authorized the creation of a wholly-owned subsidiary to pursue direct and indirect investment opportunities via a Joint Venture (JV) agreement with Shircoo, Inc. Shircoo is a Los Angeles based private equity firm. The JV will center on opportunities in Emerging Technologies and Consumer Trends.

Fundamentally, HISP has taken advantage of innovation to re-shift its focus into a brand accelerator Company with the aim of increasing its portfolio of all-natural exotic flavored beverage and snack brands. The HISP accelerator backs beverage/snack companies that it can acquire by building a proprietary distribution platform to enhance its own brands and position them for mass market entry.

Hispanica International Delights of America, Inc. (HISP), closed Monday's trading session at $0.44091, up 0.18%, on 13,000 volume with 11 trades. The average volume for the last 60 days is 10,818 and the stock's 52-week low/high is $0.0515/$0.595.

InnerScope Hearing Technologies, Inc. (INND)

Stockhouse, Stockopedia, InvestorsHub, Front Page Stocks, YCharts, and MarketWatch reported on InnerScope Hearing Technologies, Inc. (INND), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

OTCQB-listed, InnerScope Hearing Technologies, Inc. is a technology driven business with highly scalable B2B (Business-to-Business) and B2C (Business-to-Consumer) solutions. The Company has plans on opening, operating, and expanding a chain of audiological and retail hearing device clinics.

In September of 2017, InnerScope Advertising Agency, Inc. announced its name change to InnerScope Hearing Technologies, Inc. This change was completed and approved by FINRA (Financial Industry Regulatory Authority). The change was effective September 18, 2017. Incorporated in June 2012, InnerScope Hearing Technologies has its corporate headquarters in Roseville, California.

The Company provides a B2B SaaS (Software as a Service) based Patient Management System (PMS) software program. The design of this is to improve operations and communication with patients.

Furthermore, InnerScope offers a Buying Group experience for audiology practices. This enables owners to decrease product costs and increase their margins.

Additionally, InnerScope Hearing Technologies will compete in the DTC (Direct-to-Consumer) markets with its own line of "Hearables," and "Wearables" and leading-edge Apps on the iOS and Android markets. Basically, the Company’s mission is to innovate and deploy products and services on a scalable platform for the 360-plus million people around the Global Suffering from Hearing Impairment to create an Eco-System around the Company.

The Company’s updated business plan is to scale its infrastructure to develop and deploy a revenue eco-system strategy. This includes expanding the revenue model to other major sectors of the worldwide hearing industry.

InnerScope will create seven separate revenue generating divisions. The Company said that each division will generate revenue and be positioned for growth, thus growing the Company’s market penetration.

This past November, InnerScope Hearing Technologies announced a successful launch as part of the INND.com website a Direct-To-Consumer (DTC) E-Commerce Store for its Personal Sound Amplification Products (PSAPs) and its Hearable/Wearable hearing products. InnerScope continues to expand infrastructure and growth capabilities within its new E-Commerce platform, starting with the launch of its E-Commerce DTC Store.

In January, the Company announced it entered into a Letter of Intent (LOI) for exclusive global licensing and distribution with Eltima Software GmbH for its FlexiHub Software as it relates to remote programming of hearing aid devices. In addition, this Agreement creates an ongoing technology partnership between the two companies for future advancements, which can be used for the international audiological and hearing aid industry.

Furthermore, in January, InnerScope Hearing Technologies announced the successful launch of Hearingbenefit.com as part of its e-commerce Direct-to-Consumer sales funnel strategy. Hearingbenefit.com is a website for the Company’s Personal Sound Amplifier Products (PSAPs). Hearingbenefit.com is InnerScope’s dedicated Direct-to-Consumer website store that completes the purchase phase for the consumer.

InnerScope Hearing Technologies, Inc. (INND), closed Monday's trading session at $0.082, up 43.86%, on 20,100 volume with 2 trades. The average volume for the last 60 days is 93,119 and the stock's 52-week low/high is $0.036/$1.50.

DXI Energy, Inc. (DXIEF)

Stockhouse and Marketwired reported previously on DXI Energy, Inc. (DXIEF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

DXI Energy, Inc. is a tactical acquisitor and developer of strategic energy resources. The Company is an upstream oil and gas exploration and production enterprise. DXI Energy operates in Colorado’s Piceance Basin and in the Peace River Arch region in British Columbia (B.C.). DXI Energy has offices in Calgary, Alberta, and Vancouver, British Columbia. The Company’s shares trade on the OTC Markets Group’s OTCQB.

DXI Energy’s land holdings in the Piceance Basin highlight potential long-term regional resource value. This is as utilities develop sources of natural gas. For Kokopelli, DXI Energy retains a 25 percent Working Interest (WI) in 2,200 acres (550 net, 2 leases).

In Colorado’s Piceance Basin, the Company has 25,684 net acres. In the Peace River Arch region in B.C. it has 14,444 net acres. Regarding DXI Energy’s project areas, in the Piceance Basin in northwest Colorado, it has its Kokopelli project with 12 producing wells with extensive in place infrastructure to supplement future development as product prices dictate.

In addition, the Company has its Roan Creek project (West Piceance Hi-Pressure Mancos/Niobrara Gas). This project is 1,960 net acres, 100 percent WI. There is potential development of 8-10 high pressure Mancos/Niobrara 8200’ vertical/Hz wells. The Piceance Basin in Colorado is greater than100 miles long. It contains reserves of coal, natural gas, as well as oil shale.

The Woodrush Project in northeastern B.C. encompasses the abovementioned 14,444 net acres (20,732 gross) with 14 wells (3 oil and gas, 10 natural gas and one injector). DXI Energy is the operator. The Company owns 99 percent of the Project. This Project is now producing 315 BOEPD (30 percent oil).

DXI Energy has a multi-phase plan to expand production and landholdings at the Woodrush Project. It is implementing a remedial program at Woodrush designed to improve daily oil production to the 200 BOPD range. The Company has $13mm invested in production facilities and a related network of pipelines at the Woodrush Project.

Last week, DXI Energy provided an operational update for its Woodrush project. Mr. Robert L. Hodgkinson, DXI Energy’s Chairman & Chief Executive Officer, stated, “We are pleased to report our progress as we move forward with the drilling of high potential targets delineated by the Q3 and Q4 2017 interpretation of reprocessed 3D and 2D seismic data. The Woodrush program's objective is to significantly extend our existing oil pools south and east of the current producing wells and surface facilities. Our team is committed to maximizing both netbacks and IRR while leveraging our C$12 million of in-place infrastructure that has supported legacy production from the light oil pool discovered and producing since 2008.”

DXI Energy, Inc. (DXIEF), closed Monday's trading session at $0.09, up 20.00%, on 222,073 volume with 43 trades. The average volume for the last 60 days is 94,846 and the stock's 52-week low/high is $0.034/$0.1316.

graphic

The QualityStocks
Company Corner

graphic
graphic

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H)

The QualityStocks Daily Newsletter would like to spotlight PreveCeutical Medical Inc. (PRVCF). Today, PreveCeutical Medical Inc. closed trading at $0.40, up 60.00%, on 10,450 volume with 11 trades. The stock’s average daily volume over the past 60 days is 6,799, and its 52-week low/high is $0.01/$0.80.

NetworkNewsAudio announces the Audio Press Release (APR) titled "Promising New Approaches in Pain Management," featuring PreveCeutical Medical Inc. (OTCQB: PRVCF) (CSE: PREV) (FSE: 18H). To hear the NetworkNewsAudio version, visit LINK. To read the original editorial, visit LINK. Also today, NetworkNewsWire issued a report on how innovator PreveCeutical is offering patients novel choices in how to better the quality of their lives.

PreveCeutical Medical Inc. (PRVCF), headquartered in Vancouver, British Columbia, Canada, is a health sciences company dedicated to researching and developing innovative options for preventive and curative therapies utilizing organic and Nature Identical™ products. The company is strategically staking out select positions in the medically acute areas of diabetes and obesity, pain management, neurological disorders and cancer.

PreveCeutical Medical Inc. had its beginnings in 2009 when Stephen Van Deventer, a seasoned businessman and venture capitalist, and Kimberly Van Deventer, a successful entrepreneur, met and formed a business partnership. The duo created Cornerstone Global Partners, a venture capital and business development company, and became involved in numerous ventures including building companies such as Aurora Cannabis Inc. Taking their interest in the health and wellness market further, the pair began researching how nature and science can work together to benefit health-conscious consumers. Coining and trademarking the word "PreveCeutical" – a combination of the words "preventive" and "pharmaceutical" – was a precursor to the company's formation and incorporation in October 2015.

The company's first product was developed in the Dominican Republic and is now marketed and distributed worldwide by PreveCeutical. It is a Caribbean Blue Scorpion venom product sold under the trade name CELLB9®. This product is an oral dilute solution infused with select peptides sourced exclusively from the blue scorpion (Rhopalurus princeps) found only in Caribbean nations. The active potentiated ingredients in CELLB9, which have been used in over 40 countries for over a decade, appear to support health at a deep, cellular level. PreveCeutical's research team is using proprietary chemistry to generate Nature Identical™ peptides derived from natural compounds found in Caribbean Blue Scorpion venom with the goal of eventually treating, regulating and preventing cancer progression. Peptides are also being used to target an array of disease indications including metabolic disorders, pain management, cancers, cardiovascular and infectious diseases.

PreveCeutical is developing the first nose-to-brain delivery system of cannabinoids (CBDs) with a novel process that prepares insoluble drug-containing nano-micelles and successfully incorporating them into a proprietary sol-gels application, essentially creating a targeted drug delivery vehicle. Intended for use via a nasal spray, this unique formulation rapidly gels upon contact with mucosal tissue, which paves the way for direct nose-to-brain delivery. This novel application eliminates first pass metabolism (stomach, intestines, liver), potentially improving bioavailability and delivering extended time release formulations that may alleviate side effects of higher dosage therapeutics. This CBD-based patented formula is projected to be deployed in selected markets with licensed medical marijuana companies within 18 months.

PreveCeutical is working with four leading Australian research centers to develop a curative therapy for diabetes and obesity. This four-year program involves engineering a novel approach that selectively targets the gene that encodes for the protein PTP-1B, which is implicated and over-expressed in both type-2 diabetes and obesity. PreveCeutical's gene-silencing technology would effectively "turn off" the genetic signal which leads to the over-production of this key protein molecule, bringing it back down to safe, normalized levels, and prevent the body from storing excessive fat. Diabetes kills one person every six seconds, with more than $800 billion spent globally on the disease.

Another exciting joint venture, established with Sports 1 Marketing, will focus on the therapeutic potential in the peptides and proteins connected to the Caribbean Blue Scorpion venom to potentially treat mild brain injury concussions. Developing a therapeutic product geared towards athletes who suffer from concussions could help alleviate suffering experienced by those who are affected by head trauma.

PreveCeutical Medical's science and research team is led by Dr. Harendra (Harry) Parekh, Ph.D., who is based at the University of Queensland's (UQ) Pharmacy Australia Centre of Excellence (PACE), and Dr. Makarand Jawadekar, Ph.D., whose 28 years of R&D experience with Pfizer Inc., is applicable in his role as chief science officer. Research collaborators include Dr. Rakesh Veedu, an emerging expert internationally in the field of molecular medicine, and Professor Grant Ramm, who is currently head of a leading medical research institute located in Brisbane, Australia.

PreveCeutical Medical is partnering with leading industry experts and companies in its quest to be a leader in the preventive health sciences sector. Its Research and Development partnership with UniQuest, the main commercialization company for the University of Queensland, provides PreveCeutical with the rights to all intellectual property arising from projects created under the agreement. PreveCeutical Medical Inc.'s management team brings an extensive portfolio of research experience, product development, deep corporate strategy and capital markets leadership to the company's core. Disclaimer

PreveCeutical Medical Inc. Company Blog

PreveCeutical Medical Inc. News:

NetworkNewsAudio Announces Audio Press Release (APR) on Exciting New Solutions to Tackle Pain

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Developing Alternative Solutions in Health-Boosting Market

NetworkNewsWire Announces Publication on Innovative Approaches in Non-Addictive Analgesics

Skinvisible, Inc. (SKVI)

The QualityStocks Daily Newsletter would like to spotlight Skinvisible, Inc. (SKVI). Today, Skinvisible, Inc. closed trading at $0.025, off by 4.21%, on 138,021 volume with 20 trades. The stock’s average daily volume over the past 60 days is 235,050 and its 52-week low/high is $0.02/$0.33.

Skinvisible, Inc. (SKVI) previously announced the signing of a Letter of Intent for a proposed merger with Quoin Pharmaceuticals Limited – a partnership that could address significant unmet medical needs on the pain management market.

Skinvisible, Inc. (SKVI) through its wholly owned subsidiary Skinvisible Pharmaceuticals, Inc., is a Research and Development company whose patented Invisicare® technology can be used to revitalize or create new medical or skincare products, allowing a company that licenses Skinvisible's formulations to sell their own patented product and combat generic competitors.

A prescription dermatology product can generate $100 million or more a year, with the potential to lose 50-90% of that revenue when it goes off patent. Preserving that revenue is why the licensing of a product made with Invisicare is a very desirable option for many companies. The Company has developed a pipeline of 40 products using Invisicare, with a primary focus on optimizing the performance and increasing the value of "gold standard" dermatology drugs and licensing them to international and multi-national companies in the pharmaceutical, over-the-counter and cosmeceutical markets.

Invisicare® is a high performance topical and transdermal delivery system which enhances the delivery of drugs and other ingredients to and through the skin. The key to Skinvisible's patented technology and trademarked Invisicare® family of polymer delivery vehicles is its formula and process for combining hydrophilic and hydrophobic polymers into stable complexes in water emulsions. Invisicare® can be a key component of life cycle management, extending the life with a new patent-protected product, dramatically expanding the company's revenue stream.

Independent studies of Invisicare® have shown the following benefits:

  • Active ingredients stay on the skin for up to four hours or more and resist wash off and rub off.
  • Delivery method results in improved efficacy, reduced skin irritation and lower required dosage.
  • Unique formulations are non-drying and provide the ability to control the release of active ingredients.
  • Products form a protective barrier, which means normal skin respiration and perspiration occur and the product wears off as part of the skin's natural exfoliation process.

Terry Howlett, President, founder and CEO of Skinvisible Inc., said the Company has more than 15 years of scientific research and product development experience. All development is conducted using stringent pharmaceutical standards. The Company has licensed a number of its formulations including a prescription hemorrhoid cream in the USA, its anti-aging Kintari® line of products and DermSafe®, its non-alcohol hand sanitizer to a licensee in China. Producing licensed products for the booming cannabis industry is also an important element of the company's business strategy.

Skinvisible's foray into the rapidly expanding market for medicinal and recreational cannabis products is already underway with the development of the company's first hemp-derived CBD (cannabidiol) products. Skinvisible has negotiated an exclusive licensing deal in Canada with Canopy Growth Corporation, one of the world's leading cannabis companies. As part of the company's overall growth strategy, Skinvisible is also negotiating with a Licensed Producer in Las Vegas where Skinvisible scientists will develop THC (tetrahydrocannabinol) products for the legal recreational and medical marijuana market for the USA. Notably, Skinvisible is actively pursuing potential licensees through-out the world where medical cannabis is legal. These licensees will have the exclusive right to manufacture and distribute Skinvisible's cannabis products within their territory.

"We are excited about the results we are already seeing just with our hemp-derived CBD products," Howlett says. "Our science shows that our CBD products release almost four times that of market leaders and our transdermal product had an 81% penetration rate at 6 hours. These results are significant and provide the difference between ordinary cannabis products and ones enhanced by Invisicare."

The Company's business model includes out-licensing its formulations for a development fee, license fee and on-going royalties in addition to selling its Invisicare polymers to its licensees. Disclaimer

Skinvisible, Inc. Blog

Skinvisible, Inc. News:

Skinvisible, Inc. (SKVI), Quoin Pharmaceuticals Proposed Merger to Address Opioid Pain Management Market

NetworkNewsBreaks – Skinvisible, Inc.’s (SKVI) DermSafe Offers Long-term Protection Against H3N2 Flu Virus

DermSafe from Skinvisible, Inc. (SKVI) Kills Killer Flu Virus H3N2 For Up to Four Hours

ABcann Global (TSX.V:ABCN) (OTCQB:ABCCF)

The QualityStocks Daily Newsletter would like to spotlight ABcann Global (ABCCF). Today, ABcann Global closed trading at $1.9337, off by 0.84%, on 1,556,454 volume with 1,952 trades. The stock’s average daily volume over the past 60 days is 824,315 and its 52-week low/high is $0.6171/$3.2929.

ABcann Global (TSX.V:ABCN) (OTCQB:ABCCF) shares shot up to $2.95 on the TSX-V this morning before a quick halt and resume by the national self-regulatory organization which oversees all investment dealers and trading activity on debt and equity marketplaces in Canada, IIROC.

ABcann Global (TSX.V: ABCN) (OTCQB: ABCCF) ABcann Medicinals, Inc. is a globally licensed, cost efficient producer of premium quality organic standardized medicinal cannabis. One of the earliest licensed Canadian medical marijuana producers under Canada's federally-controlled Access to Cannabis for Medical Purposes Regulations (ACMPR), ABcann has five years of operating experience in the burgeoning medical marijuana space. The company currently owns and operates a fully functioning 14,500 square foot facility in Napanee, Ontario. Additionally, ABcann owns 65 acres of real estate with proper zoning and existing infrastructure in place to support the construction of another production facility of up to one million square feet.

In a November 2016 report, market research firm Canaccord Genuity Group forecasted that the medical marijuana market in Canada could see sales in excess of $8 billion by 2024, creating a sizable opportunity for the country's licensed producers (LPs). The research firm also noted that the "rigorous process of becoming a licensed producer of cannabis in Canada imposes significant barriers to entry and there will be a shortfall of supply in a legalized market in the short-term." This market barrier serves as a strategic advantage for ABcann as it prepares for its highly-anticipated IPO, which is currently scheduled for April 2017.

Canaccord's synopsis of the Canadian cannabis industry is supported by recent market activity, as companies sporting one of the illustrious Canadian government licenses for medicinal production have recorded strong growth following IPO. Canopy Growth (OTC: TWMJ), one of the largest fully-licensed Canadian marijuana growers, saw share prices skyrocket by more than 700 percent in the months following its initial offering. Aphria Inc. (OTC: APHQF), another licensed grower, climbed by more than 900 percent following its IPO. Other companies that have recorded huge growth since going public include Aurora Cannabis (OTC: ACBFF), climbing nearly 900 percent, and SupremePharma (OTC: SPRWF), which soared more than 1,300 percent.

With these market trends in mind, ABcann's impending IPO is one that prospective investors in the marijuana sector will want to explore. Recalls from some of the biggest players in the Canadian cannabis industry have highlighted the considerable learning curve that LPs face in today's market, which makes ABcann's proven track record in the market all the more noteworthy. The company has built a reputation over the years for its best-in-class standardized approach to growing cannabis, including the thoughtful omission of pesticides and a computer monitored growing technique that allows ABcann to minimize the risks of variance in its yields and ensure the creation of consistently high-quality products.

This technique, which the company calls the ABcann Advantage, has helped it record a customer retention rate of 94.7 percent alongside 30 percent month-over-month customer growth. When combined with ABcann's current yield rate, which it has measured at roughly 100 percent greater than the industry average, the company has constructed a strong foundation upon which to build a sizable presence in the global cannabis industry. This global growth potential is illustrated by ABcann's partnership with Israel's Syqe Medical, producer of the world's first selective-dose pharmaceutical grade medicinal plant inhaler. After visiting the company's production facility, Perry Davidson, founder of Syqe Medical, noted that ABcann's production technologies put it "in a class with the best in the world" in its ability to produce standardized pharmaceutical grade cannabis.

ABcann's entry into the public sector is being guided by a seasoned management team, board of directors and advisory board that feature well over a century of combined industry experience. Ken Clement, the company' founder and executive chairman, has been the key component and driving force behind ABcann's development since its inception. His vision of standardized production and dosage sets ABcann apart in the medical cannabis sector. Clement is joined on the company's management team by CEO Aaron Keay. Keay brings more than a decade of capital markets experience to ABcann, having played a role in raising approximately $250 million for public and private market issuers.

Notably, ABcann also has access to the 'Father of Cannabis Research', Raphael Mechoulam, PhD, through its board of advisors. An organic chemist and professor of medicinal chemistry at the Hebrew University of Jerusalem, Mechoulam was the first scientist to isolate both cannabidiol (CBD) and tetrahydrocannabinol (THC), and he has received more than 25 prestigious academic awards, including the Rothschild Prize in Chemical Sciences and Physical Sciences in 2012.

With more than 65 acres of growth capacity, a healthy cash balance to fund upcoming construction efforts, steady sales growth, industry-leading yield rates and an established operations team in place, ABcann is well-positioned to compete in the rapidly-expanding Canadian medicinal cannabis industry. These factors, along with the company's ongoing global expansion into the European, Australian and Israeli markets, show why ABcann Medicinals' upcoming public offering fits the bill as "Canada's Next Medical Marijuana IPO." Disclaimer

ABcann Global Blog

ABcann Global News:

ABcann Global (TSX.V:ABCN) (OTCQB:ABCCF) Sees IIROC Trade Halt and Restart on the TSX-V

ABcann Completes Acquisition of Harvest Medicine

ABcann Granted Australian Import License

AnalytixInsight Inc. (TSX.V:ALY) (OTCQB:ATIXF)

The QualityStocks Daily Newsletter would like to spotlight AnalytixInsight Inc. (ATIXF). Today, AnalytixInsight Inc. closed trading at $0.3759, even for the day. The stock’s average daily volume over the past 60 days is 38,827 and its 52-week low/high is $0.15/$0.6898.

NetworkNewsAudio announces the Audio Press Release (APR) titled "Artificial Intelligence Shakes-Up Fintech," featuring AnalytixInsight (TSXV: ALY) (OTCQB: ATIXF). To hear the NetworkNewsAudio version, visit LINK. To read the original editorial, visit LINK.

AnalytixInsight Inc. (TSX.V: ALY) (OTCQB: ATIXF) is an artificial intelligence (AI) company that transforms data into knowledge. The company has developed a proprietary, machine-learning technology that algorithmically analyzes big data and distills it into actionable insights. AnalytixInsight has strategic initiatives in fintech, blockchain and workflow analytics, and its technology is scalable and extendable to virtually any data-driven industry such as sports, communications, healthcare, insurance or government.

The company's flagship product – CapitalCube.com – is a financial portal providing comprehensive company analysis including on-demand fundamental research, portfolio evaluation and screening tools on over 50,000 global equities and North American ETFs. CapitalCube's online portal is designed to empower investment ideas by providing in-depth analysis, peer-to-peer performance evaluations, accounting and earnings reports, dividend strength and AI-supported information about likely corporate actions such as dividend changes, share buybacks and acquisitions. AnalytixInsight provides a robust technology that is frequently rebalanced to maintain a desired risk profile, matching risk to ideal ETF exposure, with regular compliance reporting.

CapitalCube's freemium pricing model allows free access to basic financial information, with additional in-depth analysis and predictive analytics provided at a rate of $25 per month, and customized peer analysis for $300 per month. CapitalCube publishes 3,000 articles daily and has multi-language capabilities. Thomson Reuters and Africa Investor have recently been added to the growing network of content partnerships that already includes Euronext NV, Yahoo Finance and The Wall Street Journal.

Euclides Technologies is a subsidiary company focused on Field Service Management software solutions, led by a team with decades of experience in developing and implementing workforce management solutions for large global corporations. With worldwide customers representing over 100,000 field service personnel across multiple industries, Euclides Technologies has a deep understanding of the increasing amount of data generated within the industry, as well as the analytics solution offerings to transform that data into knowledge.

MarketWall is a Fintech subsidiary that develops integrated software solutions as part of an ecosystem of smart devices that includes PCs, tablets, smart phones, wearable mobile devices and Smart TV. AnalytixInsight Inc. has joint ownership in MarketWall together with Intesa Sanpaolo, Italy's largest retail bank which has over 4,000 branches and a market capitalization of $40 billion Euros. MarketWall is expected to deploy its real-time stock trading and mobile banking app to Intesa Sanpaolo's 12.6 million customers in six European countries during 2018. The mobile stock trading application will directly interface with Intesa Sanpaolo's established MarketHub trading platform. As a Samsung Global Partner, the MarketWall app is preloaded in mobile devices in certain areas in Europe.

AnalytixInsight is currently evaluating and pursuing Blockchain initiatives which are contiguous with its artificial intelligence platform, to use a distributed ledger technology to reduce transaction costs and settlement times for its users, partners, and subsidiaries. The Company believes these initiatives will enhance current revenues being received from existing multi-year agreements with its partners. Disclaimer

AnalytixInsight Inc. Blog

AnalytixInsight Inc. News:

NetworkNewsAudio Announces Audio Press Release (APR) on Promising AI Solutions in Financial Technology

NetworkNewsBreaks – AnalytixInsight Inc. (TSX.V: ALY) (OTCQB: ATIXF) Assesses Opportunities in the Shifting Data Landscape

NetworkNewsBreaks – AnalytixInsight Inc. (TSX.V: ALY) (OTCQB: ATIXF) Aims to Boost Existing Revenues through Blockchain Technology Initiatives

ChineseInvestors.com, Inc. (CIIX)

The QualityStocks Daily Newsletter would like to spotlight ChineseInvestors.com, Inc. (CIIX). Today, ChineseInvestors.com, Inc. closed trading at $0.68, off by 1.45%, on 108,120 volume with 112 trades. The stock’s average daily volume over the past 60 days is 250,320 and its 52-week low/high is $0.40/$1.99.

ChineseInvestors.com (CIIX) today announced that its wholly-owned foreign enterprise CBD Biotechnology Co. Ltd. ("CBD Biotech") will launch 4 new hemp infused skin care products and a cutting-edge magnetic mask for the China Market in February 2018. Also today, NetworkNewsWire issued a report on the company detailing how CIIX is continuing its commitment to cryptocurrency education and awareness for the Chinese-speaking community. Its educational services seek to answer the average person’s curiosity while simultaneously providing skilled investors with up-to-date news on digital currency.

Founded in 1999, ChineseInvestors.com, Inc. (CIIX) has become a leading financial information website for Chinese-speaking investors in the United States and China. Recognizing unprecedented opportunities in the U.S. cannabis industry, CIIX is also laying the groundwork to capitalize on growing demand for cannabidiol (CBD)-based nutrition and health products.

Through its primary website, www.ChineseInvestors.com, CIIX offers a variety of investor education products and services, including real-time market commentary, analysis and educational related services in Chinese language character sets; consultative services to smaller private companies considering becoming a public company; and advertising and public relations related support services.

At the center of this initiative is the ChineseInvestors Method, a unique integration of a disciplined investing process, web-based tools, personalized instructions and support. Using this strategy, CIIX provides reliable market information to help investors make informed investment decisions and meet their individualized financial goals.

CIIX is also leveraging its financial expertise to enter into the burgeoning CBD industry, which within a few years has grown from a relatively invisible sector to a billowing market expected to reach $2.1 billion in consumer sales by 2020.

The increasing demand for CBD-based products is a catalyst for innovative business endeavors. To this accord, CIIX has established a three-year development plan to capitalize on the convergence of CBD and the nutrition and health products market in mainland China, where the benefits of CBD oil have not been widely recognized.

Under a wholesale agreement with a reputable CBD health brand, CIIX is launching the world's first online CBD health products store published in the Chinese language. The site, www.ChineseCBDoil.com, caters to a growing number of Chinese people awakening to the numerous health benefits of CBD oil for treatment of a variety of conditions such as anxiety, stress, poor sleep, Alzheimer's disease, and more. CIIX expects to launch this website at the end of January 2017, and plans to sell CBD-infused products via online and in-store.

In conjunction, CIIX's cannabis-focused "Yelp"-style mobile app is in development as a platform for Chinese people to review and discuss various cannabis products. The app will be the first marijuana social media mobile app designed for Chinese-speaking customers worldwide. Disclaimer

ChineseInvestors.com, Inc. Blog

ChineseInvestors.com, Inc. News

ChineseInvestors.com, Inc. Announces its Wholly-Owned Foreign Enterprise, CBD Biotechnology Co. Ltd.'s New Luxury Skincare Products Have Been Approved by the CFDA and Will Launch in China in February 2018

ChineseInvestors.com, Inc. (CIIX) Offering Innovative Access to Cryptocurrency

CannabisNewsBreaks – ChineseInvestors.com, Inc. (CIIX) Aims to Double Revenue, Expand in 2018

Global Payout, Inc. (GOHE)

The QualityStocks Daily Newsletter would like to spotlight Global Payout, Inc. (GOHE). Today, Global Payout, Inc. closed trading at $0.03, off by 7.69%, on 11,284,934 volume with 390 trades. The stock’s average daily volume over the past 60 days is 15,234,277, and its 52-week low/high is $0.009/$0.16.

Global Payout, Inc. (GOHE) is pleased to announce the appointment of Bill Rochfort, as President & EVP Sales to its newly formed logistics subsidiary, SecurCapital Corp. headquartered in Los Angeles, a leading international commerce gateway. SecurCapital will focus on logistics supply chain finance services introducing a disruptive "one-click solution" offering Fintech and Blockchain services in the underserved trillion-dollar logistics marketplace.

Global Payout, Inc. (GOHE) provides comprehensive payment solutions that can be fully customized for virtually any domestic and international organization distributing money worldwide. The company is committed to enabling global access to technology for optimizing financial transactions and delivering a global financial eco-system with top-tier banking institutions and the highest level financial technology partnerships.

Today, more than ever before, commercial enterprises and government institutions need powerful financial technology solutions that have the flexibility to deliver innovative customer centric services and drive operational efficiency gains throughout the organization. The Global Reserve Platform is Global Payout's fully configurable "banking-in-a-box" web-based platform that can fulfill the front-to-back office processing requirements of domestic, foreign exchange and international payment service providers. This platform is designed to improve work flow, operational efficiencies, and global financial management for enterprises operating across the globe.

The Global Reserve Platform can manage practically any financial product, including core and traditional banking products, online banking, card management, mobile wallets, merchant payment processing, biometric payments and authentication management, bill payments and P2P payments, international remittances, government benefits management, loans management, FOREX, and SWIFT / ACH / SEPA payments. Powered by the Global Reserve Administrative module, the platform can be customized for enterprises across a multitude of business sectors.

Investment in financial technology (FINTECH) companies has grown dramatically in recent years with the role of today's banks shrinking and demand for improved financial solutions continuing to rise. As the industry has continued to expand rapidly, Global Payout's management team has directed its focus on identifying the most promising market sectors with FINTECH needs. The four core areas selected are logistics, small and medium enterprises (SME), banking and travel.

In 2015, Global Payout introduced MoneyTrac Technology Inc. as a majority owned subsidiary to more effectively focus on the development of financial technologies that specifically address many of the challenges that enterprises in a variety of alternative and "high-risk" market sectors are faced with in processing financial transactions. Powered by Virtu Network Solutions, the MoneyTrac Technology platform is one the most configurable and intuitive financial technology platforms available to alternative and "high-risk" enterprises and provides them with solutions that effectively manages everything from pin debit and virtual currency, to compliance and cash flow logistics.

With the global economy constantly becoming more diversified and connected, Global Payout is well positioned with the technology software solutions its team has developed to address many different needs worldwide. Management has committed itself to exploring and identifying every avenue possible for further establishing itself as a recognized leader in FINTECH solutions. Disclaimer

Global Payout, Inc. Company Blog

Global Payout, Inc. News:

Global Payout, Inc. Announces Fintech Veteran Joining its Supply Chain Finance Subsidiary SecurCapital Corp

CannabisNewsAudio Announces Audio Press Release (APR) on Profit Potential Amid Cannabis and Blockchain Market Frenzy

CannabisNewsWire Announces Publication on Innovators Taking Advantage of Cannabis and Blockchain Buzz

Petroteq Energy Inc. (TSX.V:PQE) (OTCQX:PQEFF)

The QualityStocks Daily Newsletter would like to spotlight Petroteq Energy Inc. (PQEFF). Today, Petroteq Energy Inc. closed trading at $1.0799, off by 10.43%, on 53,540 volume with 95 trades. The stock’s average daily volume over the past 60 days is 100,085, and its 52-week low/high is $0.015/$1.8892.

Petroteq Energy Inc. (TSX.V:PQE) (OTCQX:PQEFF) announced today that the Company has received funds equal to the first tranche of the financing contemplated in the memorandum of understanding (the “MOU”) with Deloro Energy LLC (“Deloro”), previously announced by the Company on November 23, 2017.

Petroteq Energy Inc. (TSX.V: PQE) (OTCQB: PQEFF), with headquarters in Canada, seeks to create the world's largest pure-play cobalt exploration and development company. The company's current focus is on its Greater Cobalt Project located in Silver Centre, Ontario. The company is also in the midst of a three-way merger with Cobalt One Ltd. and CobalTech Mining Inc. and on completion First Cobalt will control over 10,000 hectares of prospective land and 50 historic mining operations in the Cobalt Camp in Ontario, Canada, as well as a mill and a permitted refinery facility.

The merger agreements with Cobalt One Ltd. and CobalTech Mining Inc., announced earlier this year, will result in a combined land position of more than 10,000 hectares (nearly 25,000 acres) in the Cobalt Camp containing approximately 50 past cobalt/silver producers and working mines. Initial test results from a mineralogical assessment of sample material taken from various historical mines located throughout the Cobalt Camp show both cobalt-rich and silver-rich mineralization styles. Samples taken at the former Bellellen mine, located within the Greater Cobalt Project in Ontario, show high grade cobalt assays, prompting First Cobalt to increase its drilling program at that site.

Petroteq Energy Inc. is moving quickly to leverage its potential against an economic background that estimates global consumption for refined cobalt is set to grow at an average rate of approximately 5 percent per annum for the next 10 years. The electric vehicle market, in particular, is driving this sector since more than 50 percent of the world's current production of cobalt is used in the manufacture of rechargeable lithium-ion batteries. The global lithium-ion battery market, as estimated by Zion Market Research, indicates the value at around USD $31 billion in 2016 and is expected to generate revenue of nearly USD $68 billion by end of 2022, growing at a compound annual growth rate of slightly above 17 percent.

The company's clear pathway to production and cash flow generation includes being one of only four fully permitted cobalt extraction refineries in Canada with significant material and processing infrastructure on site. With the price of cobalt increasing significantly and its importance in the growing battery market underpinning a strong long-term demand forecast, Petroteq Energy Inc. and its mining interests are primed for success.

Petroteq Energy Inc. President and CEO Trent Mell, a mining executive and capital markets professional with extensive international transactional experience, is joined by a team of reputable and seasoned deal-makers, mine builders and mine operators with decades of global experience in exploration, business development, geoscience, engineering and finance. Disclaimer

Petroteq Energy Inc. Company Blog

Petroteq Energy Inc. News:

Petroteq Energy Inc. Receives $2.5 Million from Deloro

Petroteq Energy Receives Approval as Government Contractor for State of Utah

NetworkNewsBreaks – Petroteq Energy Inc. (TSX.V: PQE) (OTCQX: PQEFF) Devoted to Improving Transparency, Productivity through Blockchain-based Platform

First Cobalt Corp. (TSX.V:FCC) (OTCQB:FTSSF)

The QualityStocks Daily Newsletter would like to spotlight First Cobalt Corp. (FTSSF). Today, First Cobalt Corp. closed trading at $0.7246, off by 10.42%, on 619,956 volume with 399 trades. The stock’s average daily volume over the past 60 days is 283,323, and its 52-week low/high is $0.3148/$1.3041.

First Cobalt Corp. (FTSSF) is pleased to announce positive drill results from its 2017 drill program, intersecting over 30 metres of disseminated cobalt mineralization in the southern part of the Canadian Cobalt Camp. Multiple drill intercepts in this area demonstrate that cobalt mineralization likely occurs as a broad zone, over approximately 350 metres of strike length associated with the historically mined Woods Vein and other transecting structures.

First Cobalt Corp. (TSX.V: FCC) (OTCQB: FTSSF), with headquarters in Canada, seeks to create the world's largest pure-play cobalt exploration and development company. The company's current focus is on its Greater Cobalt Project located in Silver Centre, Ontario. The company is also in the midst of a three-way merger with Cobalt One Ltd. and CobalTech Mining Inc. and on completion First Cobalt will control over 10,000 hectares of prospective land and 50 historic mining operations in the Cobalt Camp in Ontario, Canada, as well as a mill and a permitted refinery facility.

The merger agreements with Cobalt One Ltd. and CobalTech Mining Inc., announced earlier this year, will result in a combined land position of more than 10,000 hectares (nearly 25,000 acres) in the Cobalt Camp containing approximately 50 past cobalt/silver producers and working mines. Initial test results from a mineralogical assessment of sample material taken from various historical mines located throughout the Cobalt Camp show both cobalt-rich and silver-rich mineralization styles. Samples taken at the former Bellellen mine, located within the Greater Cobalt Project in Ontario, show high grade cobalt assays, prompting First Cobalt to increase its drilling program at that site.

First Cobalt Corp. is moving quickly to leverage its potential against an economic background that estimates global consumption for refined cobalt is set to grow at an average rate of approximately 5 percent per annum for the next 10 years. The electric vehicle market, in particular, is driving this sector since more than 50 percent of the world's current production of cobalt is used in the manufacture of rechargeable lithium-ion batteries. The global lithium-ion battery market, as estimated by Zion Market Research, indicates the value at around USD $31 billion in 2016 and is expected to generate revenue of nearly USD $68 billion by end of 2022, growing at a compound annual growth rate of slightly above 17 percent.

The company's clear pathway to production and cash flow generation includes being one of only four fully permitted cobalt extraction refineries in Canada with significant material and processing infrastructure on site. With the price of cobalt increasing significantly and its importance in the growing battery market underpinning a strong long-term demand forecast, First Cobalt Corp. and its mining interests are primed for success.

First Cobalt Corp. President and CEO Trent Mell, a mining executive and capital markets professional with extensive international transactional experience, is joined by a team of reputable and seasoned deal-makers, mine builders and mine operators with decades of global experience in exploration, business development, geoscience, engineering and finance. Disclaimer

First Cobalt Corp. Company Blog

First Cobalt Corp. News:

First Cobalt Intersects Broad Cobalt Mineralization at the Keeley Mine

Canadian Silver Hunter Inc. Reports 25 Metres of Mineralization Intersected at Keeley Mine

NetworkNewsBreaks – First Cobalt Corp. (TSX.V: FCC) (OTCQB: FTSSF) Announces Positive Results from 2017 Drill Program

graphic

Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters

graphic

1.

Schaeffer's
(UVXY) +66.21%

2.

NetworkNewsWire
(PRVCF) +60.00%

3.

QualityStocks
(INND) +43.86%

graphic
By The Numbers Charts
QualitystockTwits

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors
















 

The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.

 

About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251